TDSPharm Co

TDSPharm Co FCF/Debt

The Free Cash Flow to Debt Ratio of TDSPharm Co (464280.KQ) as of Oct 28, 2026 is 52.89 %. In the previous year, Free Cash Flow to Debt Ratio was 43.99 % — a change of 20.23% (higher).

FCF/Debt

52.89 %

YoY

20.23%

Last updated:

Free Cash Flow to Debt Ratio of TDSPharm Co is 2024 52.89 % . Free Cash Flow to Debt Ratio of TDSPharm Co was 2023 43.99 % . It decreases by 20.23% higher compared to the previous year.

The TDSPharm Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2022
33.75 KRW
Jan 1, 2023
43.99 KRW
Jan 1, 2024
52.89 KRW
The TDSPharm Co FCF/Debt history
YEARFCF/DebtYoY
52.89 %+20.23%
43.99 %+30.35%
33.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Free Cash Flow to Debt Ratio of TDSPharm Co is 52.89 % in 2024.

Free Cash Flow to Debt Ratio of TDSPharm Co changed from 43.99 % to 52.89 %, representing a 20.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's TDSPharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — TDSPharm Co

All Key Metrics — TDSPharm Co